Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), emphasizing the company's transition from commissioning into early utilization at its Galesburg facility. According to the announcement, Burcon has moved past the commissioning phase and launched commercial production across its Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein lines during fiscal year 2026. The company reported revenue of $0.83 million in the fourth quarter of fiscal 2026, up sequentially from $0.74 million in the third quarter. Management indicated that current-quarter sales are tracking toward approximately 50% sequential growth based on April and May activity.
Burcon also set a new production record, with daily output roughly 60% above January-March levels. As volume builds, the margin opportunity is expected to come from better utilization, a steadier production cadence, and start-up costs moving out of the run-rate cost structure, rather than pricing alone. The company now has over 30 purchasing customers and more than 200 active projects across pea, canola, and fava applications, signaling broadening customer traction.
Funding supports the Galesburg scale-up, with $6.9 million completed, $3.0 million undrawn, and management targeting $10 million of calendar year 2026 sales. The full announcement, including downloadable images and bios, is available here.
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets (member FINRA), offers a full spectrum of investment banking services. For more information, contact Stonegate at (214) 987-4121 or via email at info@stonegateinc.com.
